H-G. Kopp

2086eTiP TACTI-004, a double-blinded, randomised phase III trial of eftilagimod alfa plus pembrolizumab (P) + chemotherapy (C) vs placebo + P + C in 1st line advanced/metastatic NSCLC

H-G. Kopp, T.D. Clay, T. Fuereder, L. Vila Martinez et autres

1300P Treatment sequences in BRAF-V600-mutant non-small cell lung cancer: First-line targeted therapy versus first-line (chemo-) immunotherapy

M. Wiesweg, Ali Alaffas, Anna Rasokat, Felix Carl Saalfeld et autres

de, us (code pays fourni par la source)

196P Randomized phase II study of trabectedin/olaparib compared to physician’s choice in subjects with previously treated advanced or recurrent solid tumors harboring DNA repair deficiencies

R. Schlenk, Marc Rübsam, M-V. Teleanu, Stephan Richter et autres

de (code pays fourni par la source)

54P Efficacy of first-line immunotherapy for non-small cell lung cancer with MET exon 14 skipping according to PD-L1 expression

Maria Di Blasi, J.B. Kuon, H Lüders, D Misch et autres

METΔ14ex is the driver alteration for approximately 3% of non-small cell lung cancers (NSCLC) and associated with a higher PD-L1 expression, but unclear benefit from immunotherapy (IO). Seventy-eight consecutive patients with metastatic NSCLC harboring METΔex14 who received first-line IO as monotherapy or …

de (code pays fourni par la source)

1405P Sotorasib in KRAS G12C-mutated NSCLC: A multicenter real-world experience from the expanded access program in Germany

F.C. Althoff, Jan Stratmann, Paula Doebel, Ali‐Nuri Hünerlitürkoglu et autres

de (code pays fourni par la source)

487P Randomized phase II study of trabectedin/olaparib compared to physician’s choice in subjects with previously treated advanced or recurrent solid tumors harboring DNA repair deficiencies

Christoph E. Heilig, M-V. Teleanu, Irfan A. Bhatti, Susan Richter et autres

de (code pays fourni par la source)

1528P Prospective IAWS registry to optimize either neo- or adjuvant treatment strategies for adult patients with large sized, high grade soft tissue sarcoma (NRSTS)

J. T. Hartmann, H-G. Kopp, Volker Budach, Viktor Grünwald et autres

de (code pays fourni par la source)

1550P A post hoc analysis of the EPAZ trial: The prognostic role of geriatric variables in elderly soft tissue sarcoma (STS) patients

Rainer Hamacher, X. Liu, Markus K. Schuler, Leopold Hentschel et autres

de, be (code pays fourni par la source)

1424MO Perioperative FLOT plus ramucirumab versus FLOT alone for resectable esophagogastric adenocarcinoma– Updated results and subgroup analyses of the randomized phase II/III trial RAMSES/FLOT7 of the German AIO and Italian GOIM

S-E. Al-Batran, Ralf‐Dieter Hofheinz, Harald Schmalenberg, Dirk Strumberg et autres

de, it (code pays fourni par la source)

1912TiP NICITA: Nivolumab with chemotherapy in pleural mesothelioma after surgery

Rajiv Shah, Laura V. Klotz, Manuel Feißt, Martina Schneider et autres

de (code pays fourni par la source)

Supplementary Material for: Frequency of Hypoglycaemia after Different Bariatric Surgical Procedures

Johanna Brix, H-G. Kopp, Florian Höllerl, G. Schernthaner et autres

Objectives: The frequency of postprandial hypoglycaemia after different operative procedures of bariatric surgery (BS) is unknown, although this complication is potentially dangerous. Predictors and severity of hypoglycaemia after Roux-en-Y gastric bypass (RYGB), sleeve gastrectomy, and gastric banding were investigated in a large …

A randomized, double-blind, multi-center phase III study evaluating paclitaxel with and without RAD001 in patients with gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC)

Claudia Pauligk, Sylvie Lorenzen, Thorsten Oliver Goetze, Jorge Riera Knorrenschild et autres

de (code pays fourni par la source)